TY - JOUR
T1 - Initial experience of TAS-102 chemotherapy in Australian patients with Chemo-refractory metastatic colorectal cancer
AU - Jalali, A.
AU - Gard, G.
AU - Banks, S.
AU - Dunn, C.
AU - Wong, H. L.
AU - Wong, R.
AU - Lee, M.
AU - Gately, L.
AU - Loft, M.
AU - Shapiro, J. D.
AU - Kosmider, S.
AU - Tie, J.
AU - Ananda, S.
AU - Yeung, J. M.
AU - Jennens, R.
AU - Lee, B.
AU - McKendrick, J.
AU - Lim, L.
AU - Khattak, A.
AU - Gibbs, P.
N1 - Funding Information:
Funding: The analysis was conducted with support from an unrestricted grant from Servier. The authors have indicated no conflicts of interest.
Publisher Copyright:
© 2021
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2022/4
Y1 - 2022/4
N2 - For patients with refractory metastatic colorectal cancer (mCRC) treatment with Trifluridine/Tipiracil, also known as TAS-102, improves overall survival. This study aims to investigate the efficacy and safety of TAS-102 in a real-world population from Victoria, Australia. A retrospective analysis of prospectively collected data from the Treatment of Recurrent and Advanced Colorectal Cancer (TRACC) registry was undertaken. The characteristics and outcomes of patients receiving TAS-102 were assessed and compared to those enrolled in the registration study (RECOURSE). Across 13 sites, 107 patients were treated with TAS-102. The median age was 60 years (range: 31-83), compared to 63 for RECOURSE. Comparing registry TAS-102-treated and RECOURSE patients, 75% vs 100% were ECOG performance status 0-1, 74% vs 79% had initiated treatment more than 18 months from diagnosis of metastatic disease and 36% vs 49% were RAS wild-type. Median time on treatment was 10.4 weeks (range: 1.7-32). Median progression-free survival (PFS) was 3.3 months compared to 2 months in RECOURSE, while median overall survival was the same at 7.1 months. Two patients (2.3%) had febrile neutropenia and there were no treatment-related deaths, where TAS-102 dose at treatment initiation was at clinician discretion.TRACC registry patients treated with TAS-102 were younger than those from the RECOURSE trial, with similar overall survival observed. Less strict application of RECIST criteria and less frequent imaging may have contributed to an apparently longer PFS.
AB - For patients with refractory metastatic colorectal cancer (mCRC) treatment with Trifluridine/Tipiracil, also known as TAS-102, improves overall survival. This study aims to investigate the efficacy and safety of TAS-102 in a real-world population from Victoria, Australia. A retrospective analysis of prospectively collected data from the Treatment of Recurrent and Advanced Colorectal Cancer (TRACC) registry was undertaken. The characteristics and outcomes of patients receiving TAS-102 were assessed and compared to those enrolled in the registration study (RECOURSE). Across 13 sites, 107 patients were treated with TAS-102. The median age was 60 years (range: 31-83), compared to 63 for RECOURSE. Comparing registry TAS-102-treated and RECOURSE patients, 75% vs 100% were ECOG performance status 0-1, 74% vs 79% had initiated treatment more than 18 months from diagnosis of metastatic disease and 36% vs 49% were RAS wild-type. Median time on treatment was 10.4 weeks (range: 1.7-32). Median progression-free survival (PFS) was 3.3 months compared to 2 months in RECOURSE, while median overall survival was the same at 7.1 months. Two patients (2.3%) had febrile neutropenia and there were no treatment-related deaths, where TAS-102 dose at treatment initiation was at clinician discretion.TRACC registry patients treated with TAS-102 were younger than those from the RECOURSE trial, with similar overall survival observed. Less strict application of RECIST criteria and less frequent imaging may have contributed to an apparently longer PFS.
KW - Colorectal cancer
KW - Metastatic
KW - TAS-102
KW - Trifluridine/Tipiracil
UR - http://www.scopus.com/inward/record.url?scp=85115766858&partnerID=8YFLogxK
U2 - 10.1016/j.currproblcancer.2021.100793
DO - 10.1016/j.currproblcancer.2021.100793
M3 - Article
C2 - 34565601
AN - SCOPUS:85115766858
SN - 0147-0272
VL - 46
JO - Current Problems in Cancer
JF - Current Problems in Cancer
IS - 2
M1 - 100793
ER -
